PREVIEW: Johnson & Johnson (JNJ) earnings due 25/Jan at 11:25GMT/06:25EST

Johnson & Johnson (JNJ) Q4 2021 (USD): EPS (exp. 2.12/1.77 GAAP), Revenue (exp. 25.29bln)

KEY PHARMA SALES:

• STELARA: (exp. 2.48bln)


• DARZALEX: (exp. 1.58bln)


• IMBRUVICA: (exp. 1.17bln)


• INVEGA SUSTENNA/SUSTENNA: (exp. 1.05bln)


• REMICADE: (exp. 0.78bln)

DIVIDEND:

• Qtrly Dividend: (exp. 0.92)


• FY Dividend: (exp. 4.17)

EPS GUIDANCE:

• Q1 2021 EPS View: (exp. 2.58/2.14 GAAP)


• FY 2021 EPS View: (exp. 9.80/7.81 GAAP)

REVENUE GUIDANCE:

• Q1 2021 Revenue View: (exp. 23.82bln)


• FY 2021 Revenue View: (exp. 94.28bln)


• FY 2022 Revenue View: (exp. 97.79bln)

INDEX WEIGHT:

• 1.2% SPX weight


• 3.2% Dow weight


• Sector/Industry: Health Care/Pharmaceuticals

BROKER RATING:

• Avg Rating: 'Buy'


• Avg Price Target: USD 185.78


• Price Target Changes (last 30 days): 0 upward vs 0 downward

24 Jan 2022 - 17:00- Equities- Source: Newswires